RxDoctor Payments Data

Addisu Mesfin, MD

Orthopaedic Surgery of the Spine · Rochester, NYNPI 1154468833

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (59.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 21.8%. 2025 is the largest year on record at $16,330, 9.7 times the $1,682 reported in 2019.

$53,632in general payments, 2019–2025

Across 137 payments — averaging $391.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GS Solutions, Inc.$12K
  • Medical Device Business Services, Inc.$11K
  • Stryker$11K
  • Medtronic$7K
  • Globus Medical$7K
  • Alphatec Spine, Inc$4K
  • plus $2K from 9 others
$114,765in research payments, 2019–2025

Across 33 payments — averaging $3477.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Globus Medical$74K
  • Medacta USA, Inc.$41K
$50,000in ownership & investment interests, 2019–2025

Across 4 payments — averaging $12,500 each. An ownership or investment interest held by the physician or an immediate family member.

  • Axiomed LLC$50K

What the payments were for

  • Consulting fees$31,97060%
  • Speaking & faculty fees$3,5757%
  • Travel & lodging$10,54820%
  • Food & beverage$7,53914%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,632 in reported general payments places this provider in the 70th percentile of 161 orthopaedic surgery of the spine providers in New York.

See all orthopaedic surgery of the spine providers in New York

Medicare billing

Part B allowed, 2024
$229,168
Medicare patients
219
Services billed
775

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin145$1,377
Cyclobenzaprine Hcl79$1,290
Pregabalin56$1,222
Diclofenac Sodium16$656
Meloxicam137$409
Methocarbamol17$375
Methylprednisolone22$206
Oxycodone Hcl24$163
Tramadol Hcl25$151
Ibuprofen14$143

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery of the spine in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →